Implementation of Genomics in Substance Use Disorder Treatment

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
Tobacco Use DisorderSmoking CessationTobacco Use Cessation
Interventions
BEHAVIORAL

Genetically-Informed RiskProfile

"* Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing."

OTHER

Brief Cessation Advice

"* Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing."

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Washington University School of Medicine

OTHER

NCT04768114 - Implementation of Genomics in Substance Use Disorder Treatment | Biotech Hunter | Biotech Hunter